May 12, 2011 |
Dr. Andrew Weil, among the best-known medical doctors practicing alternative and complementary medicine, suggests researchers are ignoring an important endpoint when they evaluate the success or failure of clinical drug trials: how the patient feels about the treatment. Weil, a longtime leader in alternative -- or integrative -- medicine, is best known today for his books, blog and various products. It's been awhile since he ventured into the serious business of scientific research and medical practice.
July 23, 2006
Re "Drug Trials With a Dose of Doubt," July 16 Every scientific report of medical research ever written has been criticized in writing. This discussion is the heart and soul of the peer review process. It is disingenuous to imply that Dr. Thomas J. Walsh's two studies were designed poorly or with ulterior motives simply because of criticisms. Were we to allege scientific impropriety against every study so criticized, there would be no acceptable medical literature. The relationship between the pharmaceutical industry, the development of drugs and medical scientists has been imposed on the medical system by politically driven funding decisions.
November 16, 1993 |
The head of the Food and Drug Administration said Monday night the agency will revise its rules for clinical drug trials in the wake of a disastrous experiment on a hepatitis B vaccine in which five patients died. The agency released an internal task force report that called for changes in the design, analysis and reporting of clinical studies of so-called investigational new drugs.
August 17, 1989 |
A coalition of 15 AIDS and gay rights groups proposed criteria Wednesday for selecting patients to participate in "parallel track" trials of experimental AIDS drugs to ensure the tests "will not compete with, but rather complement," more formal studies.
January 1, 2001 |
Drug companies have pills aplenty in the pipeline, but they won't make it to market until they've been tested on humans. Finding the right patients for trials of new drugs is a costly headache, though, for pharmaceutical firms and for the federal government, which also sponsors experimental trials. Meanwhile, for people who are seriously ill, the appropriate trial can mean a shot at a new treatment that might help. This could be a job for . . . the Internet.
May 13, 2003 |
The biologically engineered drug Raptiva failed to effectively treat rheumatoid arthritis patients in a key experiment, Genentech Inc. and Xoma Ltd. said. The partners said they are halting further tests on patients with the disease, but added that they are hopeful federal regulators will approve Raptiva to treat the skin disorder psoriasis. The psoriasis market, however, is far smaller than the rheumatoid arthritis market. Shares of Berkeley-based Xoma fell 77 cents, or 14%, to $4.72 on Nasdaq.